乳腺癌抗体药物偶联物的临床应用和 前沿进展
Clinical Application and Cutting-Edge Progress of Antibody-Drug Conjugates in Breast Cancer
DOI: 10.12677/acm.2026.1662402, PDF,   
作者: 张英豪：山东医药大学第二临床医学院，山东 烟台；刘健楠, 孙 萍*：烟台毓璜顶医院肿瘤内二科，山东 烟台；林思祥*：山东医药大学烟台附属医院肿瘤科，山东 烟台
关键词: 抗体药物偶联物；乳腺癌；新型靶点；毒性管理；药物设计；ADCs； Breast Cancer； Emerging Targets； Toxicity Management； Drug Design
摘要: 乳腺癌是全球女性恶性肿瘤发病率第一的肿瘤。以往针对乳腺癌的治疗策略包括化疗、内分泌治疗、靶向治疗和放疗等，而抗体药物偶联物(antibody-drug conjugates, ADCs)的应用为乳腺癌的治疗带来了新的治疗曙光。本文全面介绍了目前ADCs在乳腺癌各分型中的临床应用，包括靶向HER2的德曲妥珠单抗(T-DXd)、维迪妥西单抗(RC48-ADC)以及靶向TROP2的戈沙妥珠单抗(SG)和芦康沙妥珠单抗(Sacituzumab Tirumotecan)等药物的疗效和毒副反应。此外还概述了ADC药物在乳腺癌治疗中的前沿靶点、最新研发的ADCs技术以及人工智能(AI)起到的关键作用，以期为乳腺癌患者提供更为精准高效的诊疗策略。
Abstract: Breast cancer is the most common malignant tumor in women worldwide. Previous treatment strategies for breast cancer include chemotherapy, endocrine therapy, targeted therapy and radiotherapy, and the application of antibody-drug conjugates (ADCs) has brought new therapeutic dawn for the treatment of breast cancer. This article reviews the current clinical applications and combination regimens of ADCs across breast cancer subtypes, focusing on the efficacy of HER2-targeted ADCs (trastuzumab deruxtecan [T-DXd], RC48-ADC) and TROP2-targeted ADCs (sacituzumab govitecan [SG], sacituzumab tirumotecan), and discusses strategies for managing the associated toxicity and drug resistance. Furthermore, it provides an overview of emerging therapeutic targets in breast cancer, innovations in ADC design and development, and the transformative role of artificial intelligence (AI), all aimed at enabling more precise and efficient diagnostic and therapeutic approaches for breast cancer patients.
文章引用：张英豪, 刘健楠, 孙萍, 林思祥. 乳腺癌抗体药物偶联物的临床应用和 前沿进展[J]. 临床医学进展, 2026, 16(6): 1835-1846. https://doi.org/10.12677/acm.2026.1662402

参考文献

[1] Waks, A.G. and Winer, E.P. (2019) Breast Cancer Treatment: A Review. JAMA, 321, 288-300. [Google Scholar] [CrossRef] [PubMed]
[2] Perou, C.M., Sørlie, T., Eisen, M.B., van de Rijn, M., Jeffrey, S.S., Rees, C.A., et al. (2000) Molecular Portraits of Human Breast Tumours. Nature, 406, 747-752. [Google Scholar] [CrossRef] [PubMed]
[3] Chau, C.H., Steeg, P.S. and Figg, W.D. (2019) Antibody-Drug Conjugates for Cancer. The Lancet, 394, 793-804. [Google Scholar] [CrossRef] [PubMed]
[4] Tamura, K., Tsurutani, J., Takahashi, S., Iwata, H., Krop, I.E., Redfern, C., et al. (2019) Trastuzumab Deruxtecan (ds-8201a) in Patients with Advanced Her2-Positive Breast Cancer Previously Treated with Trastuzumab Emtansine: A Dose-Expansion, Phase 1 Study. The Lancet Oncology, 20, 816-826. [Google Scholar] [CrossRef] [PubMed]
[5] Hurvitz, S.A., Hegg, R., Chung, W., Im, S., Jacot, W., Ganju, V., et al. (2023) Trastuzumab Deruxtecan versus Trastuzumab Emtansine in Patients with Her2-Positive Metastatic Breast Cancer: Updated Results from Destiny-Breast03, a Randomised, Open-Label, Phase 3 Trial. The Lancet, 401, 105-117. [Google Scholar] [CrossRef] [PubMed]
[6] Tolaney, S.M., Jiang, Z., Zhang, Q., Barroso-Sousa, R., Park, Y.H., Rimawi, M.F., et al. (2025) Trastuzumab Deruxtecan (t-Dxd) + Pertuzumab (P) vs Taxane + Trastuzumab + Pertuzumab (THP) for First-Line (1L) Treatment of Patients (pts) with Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Advanced/Metastatic Breast Cancer (a/mBC): Interim Results from Destiny-Breast09. Journal of Clinical Oncology, 43, BA1008. [Google Scholar] [CrossRef] 
[7] Andre, F., Park, Y.H., Kim, S.B., et al. (2025) Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer. The New England Journal of Medicine, 392, 36-47.
[8] Wang, J., Ouyang, Q., Xie, W., Niu, Z., Zhang, Q., Yan, X., et al. (2025) Abstract PS8-06: A Randomized, Open-Label Phase III Study Comparing Disitamab Vedotin (an Anti-HER2 Monoclonal Antibody-MMAE Conjugate) with Lapatinib Plus Capecitabine in Patients with HER2-Positive, Advanced Breast Cancer with Liver Metastasis. Clinical Cancer Research, 31, PS8-06. [Google Scholar] [CrossRef] 
[9] Hu, X., Zhang, J., Ouyang, Q., Zhang, Q., Li, H., Wang, X., et al. (2025) LBA24 Trastuzumab Botidotin vs Trastuzumab Emtansine (T-DM1) in HER2-Positive Unresectable or Metastatic Breast Cancer: Results from a Randomized Phase III Study. Annals of Oncology, 36, S1569. [Google Scholar] [CrossRef] 
[10] Song, E., Yao, H., Li, H., Yin, Y., Zhang, Q., Wang, S., et al. (2025) LBA19 SHR-A1811 versus Pyrotinib Plus Capecitabine in Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Advanced/Metastatic Breast Cancer (BC): A Multicenter, Open-Label, Randomized, Phase III Study (HORIZON-Breast01). Annals of Oncology, 36, S1564-S1565. [Google Scholar] [CrossRef] 
[11] Hu, X., Zhang, Q., Wang, L., Zhang, J., Ouyang, Q., Wang, X., et al. (2025) Ace-Breast-02: A Randomized Phase III Trial of ARX788 versus Lapatinib Plus Capecitabine for HER2-Positive Advanced Breast Cancer. Signal Transduction and Targeted Therapy, 10, Article No. 56. [Google Scholar] [CrossRef] [PubMed]
[12] Tsuchikama, K., Anami, Y., Ha, S.Y.Y., et al. (2022) Stepping Forward in Antibody-Drug Conjugate Development. Pharmacology & Therapeutics, 229, Article 107917. [Google Scholar] [CrossRef] [PubMed]
[13] Modi, S., Jacot, W., Iwata, H., Park, Y.H., Vidal Losada, M., Li, W., et al. (2025) Trastuzumab Deruxtecan in HER2-Low Metastatic Breast Cancer: Long-Term Survival Analysis of the Randomized, Phase 3 DESTINY-Breast04 Trial. Nature Medicine, 31, 4205-4213. [Google Scholar] [CrossRef] 
[14] Bardia, A., Hu, X., Dent, R., Yonemori, K., Barrios, C.H., O’Shaughnessy, J.A., et al. (2024) Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer. New England Journal of Medicine, 391, 2110-2122. [Google Scholar] [CrossRef] [PubMed]
[15] Rugo, H.S., Bardia, A., Marmé, F., Cortés, J., Schmid, P., Loirat, D., et al. (2023) Overall Survival with Sacituzumab Govitecan in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer (TROPICS-02): A Randomised, Open-Label, Multicentre, Phase 3 Trial. The Lancet, 402, 1423-1433. [Google Scholar] [CrossRef] [PubMed]
[16] Fan, Y., Li, H., Wang, H., Wang, S., Yu, H., Tong, Z., et al. (2025) LBA23 Sacituzumab Tirumotecan (Sac-TMT) vs Investigator’s Choice of Chemotherapy (ICC) in Previously Treated Locally Advanced or Metastatic Hormone Receptor-Positive, HER2-Negative (HR+/HER2-) Breast Cancer (BC): Results from the Randomized, Multi-Center Phase III OptiTROP-Breast02 Study. Annals of Oncology, 36, S1568-S1569. [Google Scholar] [CrossRef] 
[17] Bardia, A., Jhaveri, K., Im, S.A., et al. (2025) Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01. Journal of Clinical Oncology, 43, 285-296.
[18] Trerotola, M., Cantanelli, P., Guerra, E., Tripaldi, R., Aloisi, A.L., Bonasera, V., et al. (2013) Upregulation of Trop-2 Quantitatively Stimulates Human Cancer Growth. Oncogene, 32, 222-233. [Google Scholar] [CrossRef] [PubMed]
[19] Cortés, J., Punie, K., Barrios, C., Hurvitz, S.A., Schneeweiss, A., Sohn, J., et al. (2025) Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer. New England Journal of Medicine, 393, 1912-1925. [Google Scholar] [CrossRef] 
[20] Ouyang, Q., Rodon, J., Liang, Y., Wu, X., Li, Q., Song, L., et al. (2025) Results of a Phase 1/2 Study of Sacituzumab Tirumotecan in Patients with Unresectable Locally Advanced or Metastatic Solid Tumors Refractory to Standard Therapies. Journal of Hematology & Oncology, 18, Article No. 61. [Google Scholar] [CrossRef] [PubMed]
[21] Yin, Y., Fan, Y., Ouyang, Q., Song, L., Wang, X., Li, W., et al. (2025) Sacituzumab Tirumotecan in Previously Treated Metastatic Triple-Negative Breast Cancer: A Randomized Phase 3 Trial. Nature Medicine, 31, 1969-1975. [Google Scholar] [CrossRef] [PubMed]
[22] Yin, Y., Ouyang, Q., Yan, M., Zhang, J., Song, L., Li, W., et al. (2025) Sacituzumab Tirumotecan (sac-TMT) as First-Line Treatment for Unresectable Locally Advanced/Metastatic Triple-Negative Breast Cancer (a/mTNBC): Initial Results from the Phase II Optitrop-Breast05 Study. Journal of Clinical Oncology, 43, Article 1019. [Google Scholar] [CrossRef] 
[23] Dent, R.A., Shao, Z., Schmid, P., Cortés, J.C., Cescon, D.W., Saji, S., et al. (2025) LBA21 First-Line (1L) Datopotamab Deruxtecan (Dato-Dxd) vs Chemotherapy in Patients with Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer (mtNBC) for Whom Immunotherapy Was Not an Option: Primary Results from the Randomised, Phase III Tropion-Breast02 Trial. Annals of Oncology, 36, S1566-S1567. [Google Scholar] [CrossRef] 
[24] Pistilli, B., Mosele, F., Corcos, N., Pierotti, L., Pradat, Y., Le Bescond, L., et al. (2025) Patritumab Deruxtecan in HR+HER2-Advanced Breast Cancer: A Phase 2 Trial. Nature Medicine, 31, 3492-3503. [Google Scholar] [CrossRef] 
[25] Chen, P., Wang, B., Mo, Q., Wu, P., Fang, Y., Tian, Y., et al. (2019) The LIV-1-GRPEL1 Axis Adjusts Cell Fate during Anti-Mitotic Agent-Damaged Mitosis. eBioMedicine, 49, 26-39. [Google Scholar] [CrossRef] [PubMed]
[26] Yao, H.R., et al. (2025) The Safety, Tolerability, and Efficacy of BRY812 in Patients with Advanced Solid Tumors: Preliminary Results from the Phase I Clinical Study. Journal of Clinical Oncology, 43, 3021-3021. [Google Scholar] [CrossRef] 
[27] Song, E.W., Zheng, H.X., Zhang, H., Lu, J., Yan, M., Wu, J., et al. (2025) Association of LIV-1 Expression with Clinical Efficacy in Patients with Advanced Breast Cancers Treated with Bry812. Journal of Clinical Oncology, 43, e15005. [Google Scholar] [CrossRef] 
[28] Song, X., Shao, Y., Gu, W., Xu, C., Mao, H., Pei, H., et al. (2016) Prognostic Role of High B7-H4 Expression in Patients with Solid Tumors: A Meta-Analysis. Oncotarget, 7, 76523-76533. [Google Scholar] [CrossRef] [PubMed]
[29] Hamilton, E.P., Han, H.S., Kalinsky, K., Abuhadra, N., McAndrew, N.P., Spira, A.I., et al. (2025) Initial Phase 1 Dose Escalation Data for Emiltatug Ledadotin (Emi-Le), a Novel B7-H4-Directed Dolasynthen Antibody-Drug Conjugate. Journal of Clinical Oncology, 43, 3009-3009. [Google Scholar] [CrossRef] 
[30] Gough, M., Kwah, K.K.X., Khan, T., Ghosh, S., Sun, B., Lee, C.Y.J., et al. (2025) Receptor CDCP1 Is a Potential Target for Personalized Imaging and Treatment of Poor Outcome HER2+, Triple-Negative, and Metastatic ER+/HER2-Breast Cancers. Clinical Cancer Research, 31, 1504-1519. [Google Scholar] [CrossRef] [PubMed]
[31] Zhao, X., Li, Y., Zhang, H., Cai, Y., Wang, X., Liu, Y., et al. (2025) PAK5 Promotes the Trastuzumab Resistance by Increasing HER2 Nuclear Accumulation in Her2-Positive Breast Cancer. Cell Death & Disease, 16, Article No. 323. [Google Scholar] [CrossRef] [PubMed]
[32] Chen, L., Cen, Y., Qian, K., Yang, W., Zhou, W. and Yang, Y. (2025) Mmp1-Induced NF-κB Activation Promotes Epithelial-Mesenchymal Transition and Sacituzumab Govitecan Resistance in Hormone Receptor-Positive Breast Cancer. Cell Death & Disease, 16, Article No. 346. [Google Scholar] [CrossRef] [PubMed]
[33] Ou-Yang, Y., Ma, D., Lin, C., Yang, Y., Liu, C., Hou, J., et al. (2025) Landscape of Gene Fusions in Hormone Receptor-Positive Breast Cancer Reveals ADK Fusions as Drivers of Progression and Potential Therapeutic Targets. Cell Discovery, 11, Article No. 89. [Google Scholar] [CrossRef] 
[34] Tolaney, S.M., de Azambuja, E., Kalinsky, K., Loi, S., Kim, S., Yam, C., et al. (2025) Sacituzumab Govitecan (SG) + Pembrolizumab (Pembro) vs Chemotherapy (Chemo) + Pembro in Previously Untreated Pd-L1-Positive Advanced Triple-Negative Breast Cancer (TNBC): Primary Results from the Randomized Phase 3 ASCENT-04/KEYNOTE-D19 Study. Journal of Clinical Oncology, 43, LBA109. [Google Scholar] [CrossRef] 
[35] Li, S., Wang, L., Wang, Y., Zhang, C., Hong, Z. and Han, Z. (2022) The Synthetic Lethality of Targeting Cell Cycle Checkpoints and PARPs in Cancer Treatment. Journal of Hematology & Oncology, 15, Article No. 147. [Google Scholar] [CrossRef] [PubMed]
[36] Òdena, A., Monserrat, L., Brasó-Maristany, F., García-Galea, E., Casals, E., Molina, C., et al. (2025) Determinants of Long-Term Response to Patritumab Deruxtecan in Breast Cancer Patient-Derived Xenografts. npj Precision Oncology, 9, Article No. 393. [Google Scholar] [CrossRef] 
[37] Natangelo, S., Trapani, D., Koukoutzeli, C., Boscolo Bielo, L., Marvaso, G., Jereczek-Fossa, B.A., et al. (2024) Radiation Therapy, Tissue Radiosensitization, and Potential Synergism in the Era of Novel Antibody-Drug Conjugates. Critical Reviews in Oncology/Hematology, 195, Article 104270. [Google Scholar] [CrossRef] [PubMed]
[38] Jalali, P., Saeed, A., Taher, S. and Saeed, A. (2026) Trastuzumab Deruxtecan: Redefining Precision Oncology across HER2-Driven Cancers. Critical Reviews in Oncology/Hematology, 217, Article 105019. [Google Scholar] [CrossRef] 
[39] Fu, Q., Gu, Z., Shen, S., Bai, Y., Wang, X., Xu, M., et al. (2024) Radiotherapy Activates Picolinium Prodrugs in Tumours. Nature Chemistry, 16, 1348-1356. [Google Scholar] [CrossRef] [PubMed]
[40] Ballestín, P., López de Sá, A., Díaz-Tejeiro, C., Paniagua-Herranz, L., Sanvicente, A., López-Cade, I., et al. (2025) Understanding the Toxicity Profile of Approved ADCs. Pharmaceutics, 17, Article 258. [Google Scholar] [CrossRef] [PubMed]
[41] Dacoregio, M.I., Michelon, I., Ernesto do Rego Castro, C., Cezar Aquino de Moraes, F., Rossato de Almeida, G., Ravani, L.V., et al. (2025) Safety Profile of Sacituzumab Govitecan in Patients with Breast Cancer: A Systematic Review and Meta-analysis. The Breast, 79, Article 103853. [Google Scholar] [CrossRef] [PubMed]
[42] Wekking, D., Porcu, M., Pellegrino, B., Lai, E., Mura, G., Denaro, N., et al. (2023) Multidisciplinary Clinical Guidelines in Proactive Monitoring, Early Diagnosis, and Effective Management of Trastuzumab Deruxtecan (T-Dxd)-Induced Interstitial Lung Disease (ILD) in Breast Cancer Patients. ESMO Open, 8, Article 102043. [Google Scholar] [CrossRef] [PubMed]
[43] Tarantino, P., Modi, S., Tolaney, S.M., Cortés, J., Hamilton, E.P., Kim, S., et al. (2021) Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates: A Review. JAMA Oncology, 7, 1873-1881. [Google Scholar] [CrossRef] [PubMed]
[44] Bardia, A., Sun, S., Thimmiah, N., Coates, J.T., Wu, B., Abelman, R.O., et al. (2024) Antibody-Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer. Clinical Cancer Research, 30, 2917-2924. [Google Scholar] [CrossRef] [PubMed]
[45] National Comprehensive Cancer Network (2024) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Antiemesis. Version 2.2024. National Comprehensive Cancer Network.
https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1415
[46] Sakai, H., Tsurutani, J., Ozaki, Y., Ishiguro, H., Nozawa, K., Yamanaka, T., et al. (2025) A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Olanzapine-Based Prophylactic Antiemetic Therapy for Delayed and Persistent Nausea and Vomiting in Patients with HER2-Positive or HER2-Low Breast Cancer Treated with Trastuzumab Deruxtecan: ERICA Study (WJOG14320B). Annals of Oncology, 36, 31-42. [Google Scholar] [CrossRef] [PubMed]
[47] Meric-Bernstam, F., Bardia, A., Bossi, P., et al. (2025) Prophylaxis, Clinical Management, and Monitoring of Datoptamab Deruxtecan-Associated Oral Mucositis/Stomatitis. The Oncologist, 30, oyaf031.
[48] Tolaney, S.M., Sonpavde, G.P., Tarantino, P., Lustberg, M.B. and Rugo, H.S. (2025) Clinical Perspective on Management of Key Adverse Events with Sacituzumab Govitecan. The Oncologist, 30, oyaf311. [Google Scholar] [CrossRef] 
[49] Heist, R.S., Sands, J., Bardia, A., Shimizu, T., Lisberg, A., Krop, I., et al. (2024) Clinical Management, Monitoring, and Prophylaxis of Adverse Events of Special Interest Associated with Datopotamab Deruxtecan. Cancer Treatment Reviews, 125, Article 102720. [Google Scholar] [CrossRef] [PubMed]
[50] Zheng, X., Song, Y., Cao, Y., Zhang, X., Ge, K., Zhang, Q., et al. (2025) Systematic Analysis and Mechanistic Investigation of Cardiac Adverse Events Associated with Antibody-Drug Conjugates Using FAERS Database. International Journal of Surgery, 112, 1436-1447. [Google Scholar] [CrossRef] 
[51] Fang, P., You, M., Wen, H., Cao, Y., Zhou, W., Zhu, X., et al. (2025) Structural Basis of Nectin-4 Recognition by the Antibody-Drug Conjugate 9mw2821. Journal of Biological Chemistry, 301, Article 110816. [Google Scholar] [CrossRef] 
[52] Yang, Y., Zhou, H., Tang, L., Qiu, S., Han, Y., Ji, D., et al. (2025) Izalontamab Brengitecan, an EGFR and HER3 Bispecific Antibody-Drug Conjugate, versus Chemotherapy in Heavily Pretreated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicentre, Randomised, Open-Label, Phase 3 Study in China. The Lancet, 406, 2235-2243. [Google Scholar] [CrossRef] 
[53] Kwon, N.H., Lee, J.H., Kim, Y., Hahn, Y.S. and Kwon, I. (2025) Albubody: An Engineered ScFv Variant Platform for Site-Specific Drug Conjugation and Enhanced Tumor Efficacy. Journal of Controlled Release, 386, Article 114165. [Google Scholar] [CrossRef] [PubMed]
[54] Toh, Y., Wu, L., Tu, J., Liang, Z., Aldana, A.M., Wen, J.J., et al. (2025) Anti-Tumor Activity of Camptothecin Analog Conjugate of an Rspo4-Based Peptibody Targeting LGR4/5/6 in Preclinical Models of Colorectal Cancer. British Journal of Cancer, 133, 1218-1228. [Google Scholar] [CrossRef] [PubMed]
[55] Hamilton, J.Z., Pires, T.A., Mitchell, J.A., Cochran, J.H., Emmerton, K.K., Zaval, M., et al. (2021) Improving Antibody‐tubulysin Conjugates through Linker Chemistry and Site‐specific Conjugation. ChemMedChem, 16, 1077-1081. [Google Scholar] [CrossRef] [PubMed]
[56] Siciliano, S., Bernardi, C., Finetti, F., Guerrini, A., Monti, M.C., Morretta, E., et al. (2025) Protide-Enabled Antibody-Drug Conjugates: A Novel Platform for the Targeted Delivery of Phosphorylated Drugs. Bioorganic Chemistry, 167, Article 109260. [Google Scholar] [CrossRef] 
[57] Long, J., Shao, T., Wang, Y., Chen, T., Chen, Y., Chen, Y., et al. (2025) Pegylation of Dipeptide Linker Improves Therapeutic Index and Pharmacokinetics of Antibody-Drug Conjugates. Bioconjugate Chemistry, 36, 179-189. [Google Scholar] [CrossRef] [PubMed]
[58] Xiong, T., Jin, J., Liu, D. and Jin, C. (2025) Design, Synthesis, and Evaluation of Camptothecin-Based Antibody-Drug Conjugates with High Hydrophilicity and Structural Stability. Molecules, 30, Article 1398. [Google Scholar] [CrossRef] [PubMed]
[59] Kim, B., Byun, K.T., Cho, J., Lee, I., Park, D., Kang, T., et al. (2025) Development of Recombinant Mesozumab-CPT in That Dual-Targets Mesothelin and CP2c for Anticancer Therapy. Biomedicine & Pharmacotherapy, 193, Article 118799. [Google Scholar] [CrossRef] 
[60] Qin, Y., Lin, Y., Tian, C., Qi, Y., Wang, S., Chen, X., et al. (2025) Ph-Responsive Nanocomplex for Active Transport of aPD-1 and PTX to Enhance Cancer Chemoimmunotherapy. Nano Today, 62, Article 102710. [Google Scholar] [CrossRef] 
[61] Zhang, C., Pu, X., Teng, G., Li, F., Bai, H., Lin, K., et al. (2025) Ph‐Sensitive Metal-Organic Frameworks for the Improved Inhibition of HepG2 Cell via Folate Receptor‐Mediated Targeting and Cascaded CDT Effect. Advanced Healthcare Materials, 15, e04093. [Google Scholar] [CrossRef] 
[62] Lu, Y., Huang, W., Li, Y., Xu, Y., Wei, Q., Sha, C., et al. (2025) Leveraging Artificial Intelligence in Antibody-Drug Conjugate Development: From Target Identification to Clinical Translation in Oncology. NPJ Precision Oncology, 9, Article No. 374. [Google Scholar] [CrossRef] 
[63] Wasdin, P.T., Johnson, N.V., Janke, A.K., et al. (2025) Generation of Antigen-Specific Paired-Chain Antibodies Using Large Language Models. Cell, 188, 7206-7221.e16.
[64] Li, S., Fan, J., He, H., Zhou, R. and Liao, J. (2025) MolP-PC: A Multi-View Fusion and Multi-Task Learning Framework for Drug ADMET Property Prediction. Chinese Journal of Natural Medicines, 23, 1293-1300. [Google Scholar] [CrossRef] 
[65] Salvati, A., Melone, V., Giordano, A., Lamberti, J., Palumbo, D., Palo, L., et al. (2025) Multi-Omics Based and Ai-Driven Drug Repositioning for Epigenetic Therapy in Female Malignancies. Journal of Translational Medicine, 23, Article No. 837. [Google Scholar] [CrossRef] [PubMed]
[66] Ma, D., Dai, L., Wu, X., Liu, C., Zhao, S., Zhang, H., et al. (2025) Spatial Determinants of Antibody-Drug Conjugate SHR-A1811 Efficacy in Neoadjuvant Treatment for HER2-Positive Breast Cancer. Cancer Cell, 43, 1061-1075.E7. [Google Scholar] [CrossRef] [PubMed]

为你推荐